Annual report pursuant to Section 13 and 15(d)

Document and Entity Information

Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Mar. 25, 2019
Jun. 29, 2018
Document and Entity Information [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Amendment Description We are filing this Annual Report on Form 10-K/A (this "Amendment") to correct the Form 10/K for the year ended December 31, 2018 filed on April 1, 2019 (the "Original Filing"). The Amendment is being filed to correct all of the references to basic and diluted net loss per common share and the number of common shares used in such calculation for the year ended December 31, 2018 in the Original Filing, as well as the reference to net loss per share for the quarter ended December 31, 2018 that appears in the Notes to Financial Statements, which amounts were inadvertently transposed. Except as described above, no changes have been made to the Original Filing and this Amendment does not modify, amend or update in any way any of the financial or other information contained in the Original Filing nor does it reflect events that may have occurred subsequent to the Original Filing.    
Document Period End Date Dec. 31, 2018    
Document Fiscal Year Focus 2018    
Document Fiscal Period Focus FY    
Entity Registrant Name TITAN PHARMACEUTICALS INC    
Entity Central Index Key 0000910267    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Non-accelerated Filer    
Entity Public Float     $ 22.6
Trading Symbol TTNP    
Entity Common Stock, Shares Outstanding   13,413,628  
Entity Shell Company false    
Entity Emerging Growth Company false    
Entity Small Business true